All news

Barrington keeps Buy on CRA International

Alpha Vantage · AD HOC NEWS · · AI-summarised by FinFlash

CRA International appointed Christopher Zealey as vice president in its Life Sciences Practice, following an earlier VP appointment, expanding its commercial strategy expertise. Barrington analyst Kevin Steinke maintained a Buy rating with a USD 245.00 price target, citing second-quarter 2026 revenue growth of 12.80% to USD 210.80 million and raised fiscal 2026 constant-currency revenue guidance. The company reaffirmed its non-GAAP EBITDA margin guidance, pointing to a robust financial outlook.

Read original source

CRAI company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.